×
Customize
?
Start
Cancer Types
Quick Links
Events
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Colorectal Cancer
Featured Content
Colorectal cancer is one of the more commonly diagnosed cancers among both men and women today. Despite the fact that it most exclusively affects older persons, colorectal cancer is continuing to be diagnosed in younger and younger patients. CURE Connections wants to answer any questions you might have when it comes to managing colorectal cancer. This program includes information as shared by an expert physician, and personal accounts from patients and their caretakers who have dealt with colorectal cancer.
Danielle Ripley-Burgess
From cancer to COVID-19, our patient stories can help others take sickness and disease seriously.
Beth Fand Incollingo
Keytruda bested chemotherapy, delaying disease progression or death by 40%, in a clinical trial that led to the drug’s approval for use as a single initial treatment for patients with colorectal cancer.
Kristie L. Kahl
Andrea Dwyer spoke with CURE® about the symposium and why it is important to raise global awareness around the increasing rate of early-age onset colorectal cancer.
Danielle Ripley-Burgess
Multitasking isn't an exact science and its ok, often better, to take things one at a time on the cancer journey.
Katie Kosko
Childhood cancer survivors are developing colorectal polyps unrelated to family histories, according to new data.
Conor Killmurray
While follow-up data on the BEACON CRC study demonstrated superior overall survival for certain patients with metastatic colorectal cancer receiving Braftovi, Mektovi and Erbitux, an exploratory analysis is needed to understand if this treatment can impact a wider subset of patients.
Hannah Slater
“These long-awaited trial results will change clinical practice,” lead study author Dr. Thierry André, of the Sorbonne Université and Hôpital Saint Antoine in Paris, said in an ASCO-issued press release.
Beth Fand Incollingo
As the risk of colorectal cancer grows among those under 50, younger adults should know more about signs and screening.
Colon Cancer Coalition
People experiencing gastrointestinal symptoms or delays in colorectal cancer care should address these questions with their care team.
Ryan McDonald
The Braftovi-Erbitux combination will become the preferred second-line treatment option in treatment of adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, according to one expert.